3/2
08:20 pm
trda
Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next [Yahoo! Finance]
Medium
Report
Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next [Yahoo! Finance]
2/27
07:19 pm
trda
Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates [Yahoo! Finance]
Low
Report
Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates [Yahoo! Finance]
2/27
07:00 am
trda
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Medium
Report
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
2/25
08:00 am
trda
Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/24
07:09 am
trda
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 [Yahoo! Finance]
High
Report
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 [Yahoo! Finance]
2/24
07:00 am
trda
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
Medium
Report
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
2/4
08:10 am
trda
Aktis Oncology Appoints Biotech Industry Veteran Mary Thistle to its Board of Directors [Yahoo! Finance]
Low
Report
Aktis Oncology Appoints Biotech Industry Veteran Mary Thistle to its Board of Directors [Yahoo! Finance]
2/4
08:00 am
trda
Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/3
08:13 am
trda
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy [Yahoo! Finance]
Medium
Report
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy [Yahoo! Finance]
2/3
07:00 am
trda
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
Medium
Report
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
1/6
09:09 am
trda
Alltrna Appoints Dr. Nerissa Kreher as Chief Medical Officer to Advance tRNA Medicines for Rare Diseases [Yahoo! Finance]
Medium
Report
Alltrna Appoints Dr. Nerissa Kreher as Chief Medical Officer to Advance tRNA Medicines for Rare Diseases [Yahoo! Finance]
12/18
07:09 am
trda
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/18
07:00 am
trda
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference